Improvement of Depression With Use of ATP

Condition(s) studied

Investigational drug(s) / intervention(s)

ATP Group: Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.

Placebo Group: Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.

Study summary

This clinical study is a randomized, double-blind, placebo-controlled trial with an intervention period of 4 weeks. Participants will be patients with moderate to severe depression who meet the inclusion criteria during the screening period. After recruitment written informed consent form will be signed and the baseline evaluation will be done then the treatment period follows. The subjects will be randomly assigned to a control group (escitalopram plus normal saline(NA)) and an ATP group (escitalopram plus adenosine disodium triphosphate(ATP)) in a 1:1 ratio for treatment, with a total number of 120 recruited patients. Assessment will be carried out as an analysis of changes in Hamilton Depression Scale（HAMD-24）, cognitive function test, brain functional network, inflammatory markers, and other indicators in the first, second, and fourth week of intervention which will evaluate the effectiveness of ATP in improving moderate to severe depression preliminarily.

Eligibility

Primary outcome measure(s)

• HAMD-24 — Baseline, two weeks, and four weeks
  Changes in HAMD-24. Score range from 0-76, higher scores mean a worse outcome.

Trial sites (1)

More Nanfang Hospital, Southern Medical University trials in China

Other trials for the same condition